Form 4: Centessa Pharmaceuticals CFO Acquires 250,000 Share Options
SEC Form 4 Filing
John J. Crowley, Chief Financial Officer of Centessa Pharmaceuticals plc, acquired 250,000 share options on February 3, 2025, according to a Form 4 filing with the SEC.
Summary
- John J. Crowley, the Chief Financial Officer of Centessa Pharmaceuticals plc, filed a Form 4 with the SEC.
- The filing reports a transaction that occurred on February 3, 2025, where Crowley acquired 250,000 share options.
- These options have an exercise price of $16.90.
- The options vest in equal monthly installments starting March 3, 2025, with 1/48th of the shares vesting each month.
- The options expire on February 3, 2035.
- Following the transaction, Crowley directly owns 250,000 derivative securities (share options).
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to insider transactions, which is neutral in sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests between management and shareholders.
Stakeholder Impact
- Shareholders may view this transaction as a sign of confidence from the CFO in the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 02/03/2025 | Date of the transaction: CFO acquired 250,000 share options. |
| 03/03/2025 | First vesting date for the share options. |
| 02/03/2035 | Expiration date of the share options. |
| 02/04/2025 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.